How to Set Up Pre-Clinical Studies

March 11, 2022 | 1:00-3:00 p.m. (CT)


This café is the first of a two-part series hosted by Andrew Steinsapir, a gene therapy program lead at Deerfield Discovery and Development. Steinsapir is also the acting chief technology officer for Stealth Gene Therapy. Prior to Deerfield, he was a consultant for Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy, pharma, and investment firms. Steinsapir also worked at 4D Molecular Therapeutics, holding various positions, with his most recent role being senior process development associate I.

ASGCT Members & registrants: Watch on Demand

The second part of this series, Translating Pre-Clinical to Clinical Studies, will be held on Friday, April 8.

As with our other cafés, the recording of this talk will be available to ASGCT Members and registrants following its live production.

2022

ASGCT Policy Summit

Watch On Demand Through Oct. 27

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.